Trametinib is a mitogen-activated protein kinase 1 MEK1/MEK2 inhibitor that inhibits ERK phosphorylation in the RAS pathway and has demonstrated a reduction in NRAS-mutated AML proliferation in pre-clinical studies [94]. Here, NRAS is linked to acute myeloid leukemia.